Class action pursued concerning safety defects with GLP-1 drugs Mounjaro, Trulicity, & Zepbound
An application has been filed in Quebec to obtain authorization to institute a class action concerning the drugs Mounjaro, Trulicity, and Zepbound, alleging that the widely used diabetes and weight-loss medications may expose patients to serious health risks that were not adequately disclose…
View the post titled Class action pursued concerning safety defects with GLP-1 drugs Mounjaro, Trulicity, & ZepboundReceive Blog Posts
By subscribing to our blog, you will receive an email when a new post is added. You can unsubscribe at any time by sending an email to us at [email protected] with the word “unsubscribe” in the subject line.